Results 21 to 30 of about 11,913 (332)

Dry powder inhalation, part 1: ancient history and precursors to modern dry powder inhalers

Expert Opinion on Drug Delivery, 2022
Inhalation of herbs and other compounds has a long history but habits for medical treatment are intertwined with rituals to obtain hallucinatory effects and pleasurable sensations. Several examples of inhaled herbs, and the diseases they were used for, based on early translations of ancient manuscripts related to inhalation were found to be speculative
Anne Haaije de Boer, Paul Hagedoorn, Floris Grasmeijer   +2 more
openaire   +3 more sources

Small Airways, Big Problem: Extrafine beclomethasone/formoterol in asthma and chronic obstructive pulmonary disease

Lung India, 2021
Asthma and chronic obstructive pulmonary disease (COPD) are common chronic respiratory diseases characterized by an inflammatory process that extends from the central to peripheral airways.
Ashfaq Hasan, Priyanka Mukherjee, Sushmeeta Chhowala, Meena Lopez, Prashant N Chhajed   +4 more
doaj   +1 more source

Switching patients from other inhaled corticosteroid devices to the Easyhaler(®) : historical, matched-cohort study of real-life asthma patients [PDF]

, 2014
Peer reviewedPublisher ...
Gould, Shuna, Hutton, Catherine, King, Christine, Price, David, Thomas, Vicky, von Ziegenweidt, Julie   +5 more
core   +1 more source

Dry powder inhalation: past, present and future [PDF]

Expert Opinion on Drug Delivery, 2016
Early dry powder inhalers (DPIs) were designed for low drug doses in asthma and COPD therapy. Nearly all concepts contained carrier-based formulations and lacked efficient dispersion principles. Therefore, particle engineering and powder processing are increasingly applied to achieve acceptable lung deposition with these poorly designed inhalers. Areas
De Boer, A. H, Hagedoorn, P, Hoppentocht, M, Grasmeijer, F, Frijlink, H. W., BUTTINI, Francesca   +5 more
openaire   +3 more sources

Inhalation characteristics of asthma patients, COPD patients and healthy volunteers with the Spiromax® and Turbuhaler® devices: a randomised, cross-over study. [PDF]

, 2015
BACKGROUND: Spiromax® is a novel dry-powder inhaler containing formulations of budesonide plus formoterol (BF). The device is intended to provide dose equivalence with enhanced user-friendliness compared to BF Turbuhaler® in asthma and chronic ...
A Hardwell, AH Boer de, AR Clark, BL Laube, Dinesh Saralaya, EF Juniper, F Lavorini, GM Hawksworth, H Chrystyn, H Chrystyn, H Chrystyn, H Chrystyn, Harold Hosker, Henry Chrystyn, JL Rau, JP Koning de, KR Chapman, L Bentur, ME Broeders, ME Broeders, MH Dewar, ML Everard, PH Brown, Philip Chetcuti, RA Al-Showair, V Giraud, W Azouz, W Azouz, Wahida Azouz, WE Kamin, WM Nsour   +30 more
core   +1 more source

Comparison of serious inhaler technique errors made by device-naïve patients using three different dry powder inhalers: a randomised, crossover, open-label study [PDF]

, 2016
Background: Serious inhaler technique errors can impair drug delivery to the lungs. This randomised, crossover, open-label study evaluated the proportion of patients making predefined serious errors with Pulmojet compared with Diskus and Turbohaler dry ...
A Palander, A Papi, Anne Burden, AS Melani, BL Laube, Catherine Hutton, D Price, D Price, D Price, D Price, David B. Price, Dawn Shan, E Mehuys, Erika Sims, F Lavorini, F Yildiz, Federico Lavorini, GK Crompton, GN Rootmensen, H Al-Jahdali, H Chrystyn, Henry Chrystyn, IA Basheti, J Haughney, J Haughney, J Palen van der, J Steier, JC McElnay, JC Virchow, JL Rau, John Efthimiou, John Haughney, KG Nielsen, L Borgstrom, M Molimard, M Molimard, M Moller, M Schulte, MA Crane, Mathieu Molimard, MS Blaiss, Nicolas Roche, PN Dekhuijzen, RA Al-Showair, S Verver, Sinthia Bosnic-Anticevich, SP Newman, SZ Bosnic-Anticevich, V Giraud, V Giraud, V Giraud, W Azouz, Y Aydemir   +52 more
core   +2 more sources

Challenges Associated with the Pulmonary Delivery of Therapeutic Dry Powders for Preclinical Testing

KONA Powder and Particle Journal, 2018
Significant progress has been made over the last half-century in delivering therapeutics by the pulmonary route. Inhaled therapeutics are administered to humans using metered-dose inhalers, nebulizers, or dry powder inhalers, and each device requires a ...
Dominique N. Price, Nitesh K. Kunda, Pavan Muttil   +2 more
doaj   +1 more source

Environmental impact of inhalers for respiratory diseases: decreasing the carbon footprint while preserving patient-tailored treatment

BMJ Open Respiratory Research, 2020
Patients with asthma and Chronic Obstructive Respiratory Disease (COPD) rely on three main device classes for inhalation therapy: metered-dose inhalers (MDIs), dry powder inhalers (DPIs) and soft-mist inhalers (SMIs).
Sara Panigone, Federica Sandri, Rossella Ferri, Andrea Volpato, Elena Nudo, Gabriele Nicolini   +5 more
doaj   +1 more source

Nanoparticles in the treatment of chronic lung diseases [PDF]

, 2019
Nanoparticles, although considered a topic of modern medicine, actually have an interesting history. Currently, advances in nanomedicine hold great promise as drug carrier systems for sustained release and targeted delivery of diverse therapeutic agents.
Alexescu, Teodora G, Cosnarovici, Maria, Negrean, Vasile, Orasan, Olga H, Para, Ioana, Perne, Mirela G, Popovici, Ionela, Ruta, Victoria M, Tarmure, Simina, Todea, Doina A   +9 more
core   +2 more sources

Inhalacijska terapija u djece

Liječnički vjesnik, 2023
Inhalacijska terapija jedan je od stupova liječenja plućnih bolesti. Na dostavu lijeka u pluća utječu anatomija dišnog sustava, fizikalno-kemijska svojstva samog lijeka te čimbenici prijenosa lijeka (sredstva za dostavljanje lijeka, tehnika disanja i ...
Ivan Bambir, Nevenka Cigrovski, Drago Ćaleta, Dalibor Šarić, Andrea Vukić Dugac   +4 more
doaj   +1 more source